Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) fell 7.4% during mid-day trading on Thursday following a weaker than expected earnings announcement. The company traded as low as $14.54 and last traded at $14.6184. Approximately 5,467 shares were traded during trading, a decline of 98% from the average session volume of 233,699 shares. The stock had previously closed at $15.78.
The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). Terumo had a return on equity of 7.03% and a net margin of 9.31%. The business had revenue of $1.96 billion for the quarter, compared to analysts’ expectations of $1.94 billion.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on TRUMY. Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, Terumo presently has an average rating of “Strong Buy”.
Terumo Stock Performance
The company has a market capitalization of $22.20 billion, a price-to-earnings ratio of 31.35 and a beta of 0.82. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.37 and a current ratio of 2.19. The company’s fifty day simple moving average is $14.80 and its two-hundred day simple moving average is $14.09.
Terumo Company Profile
Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.
See Also
- Five stocks we like better than Terumo
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
